drugset / Trial / NCT02517697

Oral Nitrite Trial for Hypertension and Metabolic Syndrome

NCT02517697

Phase 2 Withdrawn Gladwin, Mark, MD
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of the study is to investigate effects of inorganic sodium nitrite on the cardiometabolic and hormonal disturbances observed in a targeted population of overweight/obese adults with metabolic syndrome and hypertension, at risk for insulin resistance and endothelial dysfunction.

Timeline

Start
2020-10
Primary completion
2021-04-13
Completion
2021-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Nitrite Small molecule 40 mg Oral